<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091127</url>
  </required_header>
  <id_info>
    <org_study_id>20150262</org_study_id>
    <nct_id>NCT03091127</nct_id>
  </id_info>
  <brief_title>Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe</brief_title>
  <official_title>Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      This study will therefore provide essential data to demonstrate the real world utilization of
      carfilzomib in routine clinical practice, including dosage, administration schedule, regimen,
      duration of treatment and reason for discontinuation in Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      The Primary Objective is to describe carfilzomib utilisation in routine clinical practice,
      including dosage, administration schedule, regimen, duration of treatment and reason for
      discontinuation.

      âˆ’ Secondary Objectives:

        -  Describe the population treated with carfilzomib in terms of demographics, multiple
           myeloma (MM) disease characteristics, treatment history, and comorbidities.

        -  Describe the safety profile of carfilzomib in routine clinical practice.

        -  Describe response to treatment as assessed by the physician and recorded in the medical
           file.

        -  Describe healthcare resource utilisation of subjects treated with carfilzomib, in terms
           of unplanned hospitalisations.

        -  Describe the reasons for choosing carfilzomib as the MM treatment of choice.

        -  Describe specific concomitant therapy (bisphosphonates, thromboprophylaxis,
           antihypertensive treatment, anti-infective treatment) and whether these therapies were
           used as prophylaxis or as treatment.

        -  Describe a cardiovascular assessment at carfilzomib regimen initiation and at occurrence
           of cardiac adverse events, where available per routine care (electrocardiogram [ECG],
           echocardiography, left ventricular ejection fraction).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">March 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carfilzomib starting dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at first administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at subsequent administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>At least one carfilzomib dose modification, escalation or reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>Reason for dose modification or delay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cycles started</measure>
    <time_frame>18 months</time_frame>
    <description>Number of carfilzomib treatment cycles started throughout study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing frequency</measure>
    <time_frame>18 months</time_frame>
    <description>Number of administrations per cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing schedule</measure>
    <time_frame>18 months</time_frame>
    <description>Timing of carfilzomib administration within treatment cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib duration of treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of carfilzomib treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Starting dose of concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Dose of combination agents (e.g. lenalidomide or dexamethasone) at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose modification for concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for frequency modification</measure>
    <time_frame>18 months</time_frame>
    <description>At least 1 change in frequency of carfilzomib administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for change in frequency of concomitant multiple myeloma therapies</measure>
    <time_frame>18 months</time_frame>
    <description>Reason for change in frequency of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Staging System (ISS) score and revised ISS stage at diagnosis and carfilzomib regimen initation</measure>
    <time_frame>18 months</time_frame>
    <description>International Staging System (ISS) score of I, II, III, or unkown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status</measure>
    <time_frame>18 months</time_frame>
    <description>ECOG performance status category at multiple myeloma diagnosis and carfilzomib regimen initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic risk profile at diagnosis</measure>
    <time_frame>18 months</time_frame>
    <description>Cytogenetic risk profile at diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain)</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of CRAB features at MM diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of comorbidities</measure>
    <time_frame>18 months</time_frame>
    <description>Diagnosed at any point in time before carflzomib regimen initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previously received anti-myeloma treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to prior treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Response to prior treatment received before initiation of carfilzomib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prior relapses</measure>
    <time_frame>18 months</time_frame>
    <description>Type of relapse (molecular, hematologic, or symptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>18 months</time_frame>
    <description>All grade 3 or above adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adverse event</measure>
    <time_frame>18 months</time_frame>
    <description>All grade 3 or above adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) changes</measure>
    <time_frame>18 months</time_frame>
    <description>ECG changes as recorded in tests performed per routine practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>18 months</time_frame>
    <description>LVEF decrease as recorded in tests performed per routine practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of antihypertensive treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing antihypertensive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of existing heart failure treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing heart failure treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to carfilzomib treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Physician-assessed response as recorded on the medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of relapse</measure>
    <time_frame>18 months</time_frame>
    <description>Molecular, hematologic or symptomatic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unplanned hospitalisations</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation or dose increase of existing heart failure treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant therapy not part of the carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Concomitant therapy not part of the carfilzomib regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned subsequent treatment regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Planned subsequent treatment regimen catergory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age</measure>
    <time_frame>18 months</time_frame>
    <description>Patient age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient sex</measure>
    <time_frame>18 months</time_frame>
    <description>Patient sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient height</measure>
    <time_frame>18 months</time_frame>
    <description>Patient height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient weight</measure>
    <time_frame>18 months</time_frame>
    <description>Patient weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI (magnetic resonance imaging) performed at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>MRI (magnetic resonance imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET-CT (positron emission tomography-computed tomography) performed at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>PET-CT (positron emission tomography-computed tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Serum M component at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Serum M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Urine M component at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Urine M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum albumin at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Serum albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum beta-2-microglobulin at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Beta-2-microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of percent of plasma cells in bone marrow at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of plasma cells in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline measurement of lactate dehydrogenase at MM diagnosis and carfilzomib regimen initiation.</measure>
    <time_frame>18 months</time_frame>
    <description>Lactate dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG (electrocardiogram)</measure>
    <time_frame>18 months</time_frame>
    <description>ECG (electrocardiogram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>18 months</time_frame>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF (left ventricular ejection fraction) assessment</measure>
    <time_frame>18 months</time_frame>
    <description>LVEF (left ventricular ejection fraction) assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computed Tomography (CT) performed at MM diagnosis and carfilzomib regiment initiation.</measure>
    <time_frame>18 Months</time_frame>
    <description>Computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation</measure>
    <time_frame>18 months</time_frame>
    <description>Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to response</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to best response</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Response status at end of follow-up</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to progression</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Frailty score</measure>
    <time_frame>18 months</time_frame>
    <description>Frailty score (fit, intermediate fit or frail) as assessed by physician and recorded on medical charts</description>
  </other_outcome>
  <other_outcome>
    <measure>Enrolment in a patient support program</measure>
    <time_frame>18 months</time_frame>
    <description>Enrolment in a patient support program whilst receiving carfilzomib treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Receipt of carfilzomib infusion outside of clinic</measure>
    <time_frame>18 months</time_frame>
    <description>Receipt of carfilzomib infusion at home at any point during carfilzomib treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of response to carfilzomib</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Multiple Myeloma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older at the time of carfilzomib initiation

          -  At least one prior line of MM treatment has been received

          -  Carfilzomib treatment has been initiated per routine practice and is currently ongoing

          -  At least one administration of carfilzomib in a combination regimen (ie, not
             monotherapy) has been received

          -  Provided written informed consent prior to abstraction of any data, in countries where
             written informed consent is required.

          -  Subjects who previously completed treatment with carfilzomib in a clinical trial, a
             compassionate use program or through routine practice, are eligible to take part in
             the study.

          -  Subjects who receive radiotherapy concurrently with carfilzomib treatment are also
             eligible to take part in the study.

          -  Subjects who initiate carfilzomib treatment on a combination regimen, subsequently
             discontinue all concomitant medications but remain on carfilzomib monotherapy in later
             cycles, remain eligible for participation in the study.

          -  Subjects who are also enrolled in other observational studies in which standard of
             care is not altered are eligible to take part in the study,

        Exclusion Criteria:

          -  Subjects who are enrolled in a carfilzomib clinical trial will not be eligible to
             additionally take part in this observational study.

          -  Subjects who are receiving carfilzomib treatment within a compassionate use program
             will not be eligible to take part in this observational study. If a subject who has
             enrolled into this observational study, also enrolls in a clinical trial in which MM
             treatment and/or disease management is protocol-specified, the subject becomes
             ineligible and the subject's data will be censored from the time the subject enrolled
             the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braunau</city>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rankweil</city>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwarzach im Pongau</city>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Steyer</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waidhofen an der Ybbs</city>
        <zip>3340</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geel</city>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haine Saint Paul - La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bagno A Ripoli (FI)</city>
        <zip>50012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barletta</city>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Livorno</city>
        <zip>57123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pagani (SA)</city>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taranto</city>
        <zip>74123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schiedam</city>
        <zip>3118 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

